The trial exists and the dosing event is confirmed by the sponsor and by independent reporting. Life Biosciences announced on 9 June 2026 that the first participant had been dosed in the Phase 1 clinical trial of ER-100, its lead epigenetic restoration therapy for optic neuropathies, described as the first time a partial epigenetic reprogramming therapy has been administered to a human.

The Boston company's announcement described ER-100 as the first cellular rejuvenation therapy using partial epigenetic reprogramming to receive FDA clearance to enter human clinical trials, targeting optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

The mechanism described in the post matches the sponsor's own description. ER-100 uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset the epigenetic code of retinal ganglion cells to more youthful patterns of gene expression, aiming to restore function rather than just slow progression.

The registry record confirms the trial's stated purpose is safety. The stated goal of the trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically open angle glaucoma and NAION.

Independent trade coverage confirms Life Biosciences dosed the first participant and that the trial will evaluate safety and tolerability.

Both cited background studies are real and are described roughly correctly. Lu et al. showed that ectopic expression of Oct4, Sox2 and Klf4 in mouse retinal ganglion cells restores youthful DNA methylation patterns and transcriptomes, promotes axon regeneration after injury, and reverses vision loss in a mouse model of glaucoma and in aged mice.

Gill et al. established a transient reprogramming strategy in which Yamanaka factors are expressed until the maturation phase before induction is abolished, achieving rejuvenation of around 30 years while retaining original cell identity overall.

That work rejuvenated the transcriptome by around 30 years as measured by a transcriptome clock, with the epigenome rejuvenated to a similar extent including H3K9me3 levels and the DNA methylation ageing clock, and fibroblasts showed partial functional rejuvenation of migration speed.

The fourth citation is also real. Núñez-Quintela, Li and Collado published "Cellular reprogramming beyond pluripotency" in Trends in Molecular Medicine, Volume 32, Issue 8, August 2026, reviewing how transient expression of reprogramming factors can reverse molecular hallmarks of aging while preserving somatic cell identity.

METHODOLOGY AND CONTEXT

Trial design (NCT07290244): Sponsor Life Biosciences Inc.; enrollment 18 estimated patients; ages 40 to 85; no healthy volunteers; primary purpose treatment; non-randomized, sequential assignment, open label; 18 participants across 3 patient groups, including an OAG low dose arm at 2 x 10^11 vg/eye.

It is a first-in-human Phase 1 trial evaluating safety and tolerability of an investigational epigenetic therapy candidate intended for age-related optic neuropathies.

Administration and duration: ER-100 is administered to one eye and activated by systemic doxycycline for eight weeks, with up to 18 participants planned, 12 with open-angle glaucoma and 6 with NAION, across four trial sites.

Endpoints: The Phase 1 study will evaluate safety and tolerability, with additional endpoints assessing visual function.

Independent drug-intelligence coverage likewise states safety and tolerability are the primary endpoints, with visual function assessments included as efficacy measures. No endpoint found in the registry record measures "reversal of cellular aging" directly in participants.

Preclinical basis: Life Biosciences' story begins with rodent experiments in which Sinclair's team used partial cellular reprogramming to restore vision after severe optic nerve injury, followed by work in non-human primates.

Company-presented primate data were described as showing that ER-100 targets retinal ganglion cells and reduces loss of visual function in a non-human primate model of NAION.

Key risk context omitted by the post: Cancer risk is the central safety concern, because the same Yamanaka factor genes believed to reprogram cells have produced teratomas, tumors sometimes containing hair, teeth and other partially formed tissue, in earlier experiments. Independent expert commentary framed the clearance in similar terms. Stem cell biologist Paul Knoepfler headlined his February 2026 piece on the clearance as a "risky, pioneering OSK rejuvenation trial."